Enovis Corporation (NYSE:ENOV – Get Free Report) has received an average rating of “Buy” from the six analysts that are covering the firm, Marketbeat.com reports. Six investment analysts have rated the stock with a buy recommendation. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $51.00.
Several equities research analysts recently weighed in on ENOV shares. Evercore ISI cut their price objective on shares of Enovis from $48.00 to $46.00 and set an “outperform” rating for the company in a research report on Tuesday, July 8th. UBS Group cut their price objective on shares of Enovis from $65.00 to $57.00 and set a “buy” rating for the company in a research report on Friday, August 8th. Wells Fargo & Company cut their price objective on shares of Enovis from $48.00 to $41.00 and set an “overweight” rating for the company in a research report on Friday, August 8th. Needham & Company LLC cut their price objective on shares of Enovis from $57.00 to $49.00 and set a “buy” rating for the company in a research report on Thursday, August 7th. Finally, Canaccord Genuity Group cut their price objective on shares of Enovis from $70.00 to $58.00 and set a “buy” rating for the company in a research report on Friday, August 8th.
Get Enovis alerts:
Get Our Latest Stock Report on Enovis
Enovis Trading Up 0.4%
Shares of Enovis stock opened at $30.47 on Friday. The firm has a 50-day moving average of $29.93 and a 200-day moving average of $32.24. The stock has a market cap of $1.74 billion, a PE ratio of -2.14 and a beta of 1.68. Enovis has a 52-week low of $25.47 and a 52-week high of $49.83. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.15 and a current ratio of 2.25.
Enovis (NYSE:ENOV – Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported $0.79 earnings per share for the quarter, topping the consensus estimate of $0.74 by $0.05. Enovis had a negative net margin of 37.80% and a positive return on equity of 6.78%. The business had revenue of $564.50 million during the quarter, compared to analysts’ expectations of $555.80 million. During the same quarter in the prior year, the business posted $0.62 earnings per share. Enovis’s revenue was up 7.5% compared to the same quarter last year. Enovis has set its FY 2025 guidance at 3.050-3.200 EPS. As a group, sell-side analysts forecast that Enovis will post 2.79 EPS for the current year.
Insiders Place Their Bets
In other Enovis news, SVP Bradley J. Tandy bought 3,200 shares of the stock in a transaction on Friday, August 22nd. The stock was purchased at an average price of $31.41 per share, with a total value of $100,512.00. Following the completion of the purchase, the senior vice president owned 43,515 shares in the company, valued at $1,366,806.15. The trade was a 7.94% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Damien Mcdonald bought 6,457 shares of the stock in a transaction on Thursday, September 11th. The shares were acquired at an average cost of $30.97 per share, with a total value of $199,973.29. Following the purchase, the chief executive officer owned 102,753 shares of the company’s stock, valued at approximately $3,182,260.41. This represents a 6.71% increase in their position. The disclosure for this purchase can be found here. Over the last 90 days, insiders acquired 12,157 shares of company stock valued at $374,760. 2.70% of the stock is currently owned by corporate insiders.
Institutional Inflows and Outflows
A number of large investors have recently added to or reduced their stakes in the business. Corient Private Wealth LLC raised its holdings in Enovis by 34.1% in the 2nd quarter. Corient Private Wealth LLC now owns 10,226 shares of the company’s stock valued at $321,000 after buying an additional 2,599 shares during the last quarter. Osaic Holdings Inc. raised its holdings in Enovis by 56.0% in the 2nd quarter. Osaic Holdings Inc. now owns 139,727 shares of the company’s stock valued at $4,382,000 after buying an additional 50,156 shares during the last quarter. Squarepoint Ops LLC raised its holdings in Enovis by 5.9% in the 2nd quarter. Squarepoint Ops LLC now owns 206,108 shares of the company’s stock valued at $6,464,000 after buying an additional 11,471 shares during the last quarter. State of Wyoming raised its holdings in Enovis by 555,600.0% in the 2nd quarter. State of Wyoming now owns 5,557 shares of the company’s stock valued at $174,000 after buying an additional 5,556 shares during the last quarter. Finally, Nomura Holdings Inc. bought a new position in Enovis in the 2nd quarter valued at approximately $586,000. Institutional investors own 98.45% of the company’s stock.
Enovis Company Profile
(Get Free Report)
Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.
See Also
Five stocks we like better than Enovis
What Does a Stock Split Mean?
Datavault AI: The New AI Contender Backed by Big Funding
What Are Dividend Champions? How to Invest in the Champions
CoreWeave: Why the New King of AI Infrastructure Has Room to Run
Stock Dividend Cuts Happen Are You Ready?
Top 3 Dividend Achievers for October: High Yields, Growth Ahead